
A pharmaceutical executive agreed Tuesday to plead guilty in an insider trading case that federal prosecutors say netted him more than $262,000 in illegal profits.
Dishant Gupta, director of data strategy and operations for French drugmaker Ipsen, plans to plead guilty to securities fraud and settle a civil lawsuit filed by the Securities and Exchange Commission, Reuters reported, citing legal papers filed in U.S. District Court in Boston.